News from targovax A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

14 May, 2020, 08:08 BST Targovax Announces That the ONCOS-102 and Durvalumab Abstract is Selected for a Poster Discussion Session at ASCO

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces ...


06 May, 2020, 06:22 BST Targovax Announces That Abstract on Interim Phase I Clinical Data From the Phase I/II Peritoneal Trial is Accepted at ASCO

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces ...


04 May, 2020, 06:23 BST Targovax Releases Update for Mesothelioma Trial Combining ONCOS-102 and Chemotherapy

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today releases...


30 Apr, 2020, 06:20 BST Targovax ASA Appoints Dr Victor Levitsky as Chief Scientific Officer

Targovax ASA (OSE: TRVX) announces the appointment of Dr Victor Levitsky, MD, PhD as Chief Scientific Officer (CSO). He will play a leading role in...


22 Apr, 2020, 06:13 BST Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses and cancer vaccines to target hard-to-treat solid...


03 Apr, 2020, 06:23 BST Targovax ASA Announces Proposed New Chairman of the Board

Targovax ASA (OSE: TRVX) announces that its nomination committee has nominated Mr. Damian Marron for election as Chairman of the Board at the...


11 Mar, 2020, 06:10 GMT Targovax ASA: Fourth Quarter 2019 Results

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...


03 Mar, 2020, 06:17 GMT Targovax Announces Completed Enrollment in the ONCOS-102 Trial in Anti-PD1 Refractory Melanoma

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...


21 Jan, 2020, 16:18 GMT Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces ...


08 Jan, 2020, 12:07 GMT Updated Press Release: Targovax and IOVaxis Therapeutics Enters Option Agreement for TG Mutant RAS Vaccine License and Clinical Development in China

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses and cancer vaccines to target hard-to-treat solid...


11 Nov, 2019, 06:28 GMT Presentation of ONCOS-102 Melanoma Data at SITC Annual Meeting

Targovax ASA (OSE: TRVX), announces that clinical data from its combination trial with ONCOS-102 and Keytruda in anti-PD1 refractory melanoma was...


07 Nov, 2019, 06:49 GMT Targovax ASA: Third Quarter 2019 Results

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...


09 Oct, 2019, 06:40 BST Targovax Selected for Oral Presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting

Targovax ASA (OSE: TRVX), announces that clinical data on the company's lead product candidate ONCOS-102, a genetically modified oncolytic adenovirus ...


08 Jul, 2019, 17:48 BST Targovax Announces Encouraging Results From Part 1 of the ONCOS-102 and Keytruda Combination Trial in Anti-PD1 Refractory Melanoma

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces...


03 Jun, 2019, 06:19 BST Targovax Announces Publication of in vivo Abscopal Effect of ONCOS-102 and Keytruda Combination

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...


23 May, 2019, 07:39 BST Targovax to Fully Focus on ONCOS Oncolytic Virus Program

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...


09 May, 2019, 06:17 BST Targovax ASA: First Quarter 2019 Results

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...


08 May, 2019, 06:25 BST Targovax Announces Completed Enrollment of ONCOS-102 Trial in Mesothelioma

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...


14 Mar, 2019, 06:20 GMT Targovax Grants Zelluna Immunotherapy an FTO License to Intellectual Property Relating to Mutant Ras T Cell Receptor Technology

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...


14 Feb, 2019, 07:11 GMT Targovax ASA: Fourth Quarter and Full Year 2018 Results

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...


21 Jan, 2019, 06:26 GMT Targovax is Invited to Present at Upcoming Investor Conferences

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that...


17 Jan, 2019, 06:21 GMT Targovax Granted European Patent for Mutant-RAS Neoantigen Platform Lead Products

Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid...


12 Dec, 2018, 16:03 GMT Targovax Presents at DNB 9th Annual Nordic Healthcare Conference

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that...


28 Nov, 2018, 06:20 GMT Targovax is Invited to Present at Upcoming Investor and Industry Conferences

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that...


16 Nov, 2018, 06:14 GMT Targovax to Present at NeoAg Summit 2018

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...